A test for a mutated gene led to the early detection of breast cancer when it resurfaced for Carole Warren -- 18 years after her first bout with the disease. The Camarillo woman was diagnosed with breast cancer in 1989.

CHICAGO -- Immunomedics, Inc., a biopharmaceutical company focused on developing monoclonal antibodies to treat cancer and other serious diseases, today announced that epratuzumab labeled with the potent radioisotope, yttrium-90 (Y-90), produced significant clinical results when given in small fractionated doses

Early detection is the best protection." It's been the mantra of breast cancer prevention messages for years. In fact the Center for Disease Control and Prevention reports that when breast cancer is discovered at an early, localized stage and treated,

Dr. Matthew Ellis stands at the dawn of personalized medicine, his work heralding a day when breast cancer patients will receive just the right treatment for their specific type of disease. Ellis, a researcher at Washington University School of Medicine

WAYNE, N.J. and EMERYVILLE, Calif. -- Bayer HealthCare Pharmaceuticals, Inc. and Onyx Pharmaceuticals, Inc. today announced the presentation of new clinical data from the early clinical trials in the development program for Nexavar(R) (sorafenib) tablets in multiple tumor types including

CHICAGO -- A drug to prevent bone loss during breast cancer treatment also substantially cut the risk that the cancer would return, results that left doctors excited about a possible new way to fight the disease. It is the first

New drug cocktails have shown promise in the fight against breast cancer, a diseases that annually kills more than half an million of women around the world, two new studies show. The research was unveiled at an annual meeting here

An international study led by researchers at the John Wayne Cancer Institute at Saint John's Health Center has found that modifications to DNA found on multiple chromosomes in tumors can help to predict outcomes in patients with early-stage rectal cancer.

CHICAGO -- Abraxis BioScience, Inc., a fully integrated, global biotechnology company, today announced the presentation of results from an ongoing single-arm, open-label, Phase II clinical trial evaluating solvent-free ABRAXANE(R) for Injectable Suspension (paclitaxel protein-bound particles for injectable suspension) (albumin bound)

Disparities in breast cancer treatment exist even among fully insured African-Amerian women and white women in Georgia, according to a study released Sunday by WellPoint, parent company of Blue Cross and Blue Shield of Georgia. The study, presented Sunday at

Hamburg -- A new study by German researchers has found conclusive evidence that vitamin D really does reduce the risk of breast cancer in women, confirming anecdotal evidence. The just-released findings of a long-term study involving 1,394 breast cancer patients

Sanofi-aventis and GEICAM (Grupo Espanol de Investigacion en Cancer de Mama) announced that for women with high-risk node-negative early stage breast cancer adjuvant treatment (post surgery) with Taxotere(R) (docetaxel) Injection Concentrate as part of the TAC regimen (Taxotere(R), doxorubicin, cyclophosphamide)